分化型甲状腺癌放射性碘治疗剂量确定的相关因素
Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.
作者信息
Hong Chae Moon, Ahn Byeong-Cheol
机构信息
1Department of Nuclear Medicine, School of Medicine, Kyungpook National University, 680, Gukchaebosang-ro, Jung-gu, Daegu, 41944 Republic of Korea.
2Department of Nuclear Medicine, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944 Republic of Korea.
出版信息
Nucl Med Mol Imaging. 2018 Aug;52(4):247-253. doi: 10.1007/s13139-018-0522-0. Epub 2018 May 2.
Abstract
Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables.
摘要
放射性碘（RAI）治疗分化型甲状腺癌已成功应用70多年。然而，关于放射性碘的使用和剂量仍存在诸多争议。目前尚无足够证据回答这些问题。基于近期的临床试验和荟萃分析，美国甲状腺协会（ATA）最新指南似乎倾向于低剂量RAI。然而，长期随访数据仍然有限，我们还应考虑其他可能影响RAI治疗疗效的因素。因此，在获得足够数据之前，有必要谨慎考虑多个患者特异性变量来确定RAI剂量。
相似文献
1
Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.分化型甲状腺癌放射性碘治疗剂量确定的相关因素
Nucl Med Mol Imaging. 2018 Aug;52(4):247-253. doi: 10.1007/s13139-018-0522-0. Epub 2018 May 2.
2
Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.比较不同剂量放射性碘消融治疗中高危分化型甲状腺癌患者的效果。
Ann Nucl Med. 2019 Jul;33(7):495-501. doi: 10.1007/s12149-019-01357-6. Epub 2019 Apr 6.
3
Radioactive iodine ablation post differentiated thyroid cancer surgery: an analysis of use and impact of the American Thyroid Association guidelines.分化型甲状腺癌手术后放射性碘消融治疗：美国甲状腺协会指南的应用与影响分析
ANZ J Surg. 2019 Nov;89(11):E502-E506. doi: 10.1111/ans.15522. Epub 2019 Oct 31.
4
Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.分化型甲状腺癌女性患者放射性碘治疗对卵巢储备功能的纵向分析。
Thyroid. 2020 Apr;30(4):580-587. doi: 10.1089/thy.2019.0504. Epub 2020 Feb 10.
5
Radioactive Iodine in Differentiated Thyroid Carcinoma: A Systematic AGREE II Clinical Practice Guideline Appraisal.放射性碘在分化型甲状腺癌中的应用：一项系统评价 AGREE II 临床实践指南。
Otolaryngol Head Neck Surg. 2024 Jan;170(1):20-33. doi: 10.1002/ohn.508. Epub 2023 Sep 11.
6
Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.放射性碘再分化治疗对既往碘难治性分化型甲状腺癌的临床疗效。
Thyroid. 2024 Jan;34(1):70-81. doi: 10.1089/thy.2023.0456. Epub 2023 Dec 12.
7
Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.放射性碘给药时机对分化型甲状腺癌患者的预后无影响。
Thyroid. 2016 Nov;26(11):1623-1629. doi: 10.1089/thy.2016.0038. Epub 2016 Sep 22.
8
Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.中危分化型甲状腺癌患者术后低剂量和高剂量放射性碘治疗的临床结局
Nucl Med Commun. 2017 Mar;38(3):228-233. doi: 10.1097/MNM.0000000000000636.
9
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?2022年欧洲甲状腺协会共识声明：分化型甲状腺癌术后放射性碘治疗的指征有哪些？
Eur Thyroid J. 2022 Jan 1;11(1):e210046. doi: 10.1530/ETJ-21-0046.
10
The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.丙硫氧嘧啶对格雷夫斯病后续放射性碘治疗的影响。
Clin Endocrinol (Oxf). 1997 Oct;47(4):425-30. doi: 10.1046/j.1365-2265.1997.2741075.x.
引用本文的文献
1
Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview.放射性碘在甲状腺分化癌中的应用：概述。
Curr Radiopharm. 2024;17(1):2-6. doi: 10.2174/0118744710249684231013072013.
2
Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.不同放射性碘剂量用于甲状腺残留组织消融后治疗的评估：一项系统综述
Iran J Pharm Res. 2022 May 14;21(1):e123825. doi: 10.5812/ijpr-123825. eCollection 2022 Dec.
3
Radioactive iodine therapy: multiple faces of the same polyhedron.放射性碘治疗：多面的同一种多面体。
Arch Endocrinol Metab. 2022 May 13;66(3):393-406. doi: 10.20945/2359-3997000000461. Epub 2022 May 12.
4
Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.分化型甲状腺癌患者接受碘-131 治疗后发生第二原发癌的发生率及相关因素：一项多中心回顾性研究。
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1661-1670. doi: 10.1007/s00259-021-05608-5. Epub 2021 Nov 13.
5
A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy.基于住院患者 131I 消融治疗后释放时间的剂量率的实用个体化辐射防护。
PLoS One. 2021 May 21;16(5):e0251627. doi: 10.1371/journal.pone.0251627. eCollection 2021.
6
Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.分化型甲状腺癌的现实生活个性化管理——多学科专家小组的实用指南
Endocrine. 2020 Nov;70(2):280-291. doi: 10.1007/s12020-020-02418-x. Epub 2020 Aug 9.
7
Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers.分化型甲状腺癌放射性碘治疗期间唾液腺损伤的减少
Nucl Med Mol Imaging. 2020 Jun;54(3):126-127. doi: 10.1007/s13139-020-00643-w. Epub 2020 May 12.
本文引用的文献
1
Quantitative performance evaluation of I PET/MRI lesion dosimetry in differentiated thyroid cancer.I 型正电子发射断层扫描/磁共振成像（PET/MRI）在分化型甲状腺癌病灶剂量学中的定量性能评估。
Phys Med Biol. 2017 Dec 19;63(1):015014. doi: 10.1088/1361-6560/aa990b.
2
Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy.放射性碘难治性分化型甲状腺癌的再分化以重新应用I-131治疗
Front Endocrinol (Lausanne). 2017 Oct 12;8:260. doi: 10.3389/fendo.2017.00260. eCollection 2017.
3
Radioactive iodine (RAI) therapy for metastatic differentiated thyroid cancer.放射性碘（RAI）治疗转移性分化型甲状腺癌。
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):279-290. doi: 10.1016/j.beem.2017.04.010. Epub 2017 May 9.
4
Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.分化型甲状腺癌甲状腺切除术后放射性碘消融：效用、剂量和毒性的文献综述
Eur Thyroid J. 2017 Jul;6(4):187-196. doi: 10.1159/000468927. Epub 2017 Mar 23.
5
I-131 biokinetics of remnant normal thyroid tissue and residual thyroid cancer in patients with differentiated thyroid cancer: comparison between recombinant human TSH administration and thyroid hormone withdrawal.分化型甲状腺癌患者残余正常甲状腺组织和残留甲状腺癌的I-131生物动力学：重组人促甲状腺素给药与甲状腺激素撤药的比较
Ann Nucl Med. 2017 Oct;31(8):582-589. doi: 10.1007/s12149-017-1188-x. Epub 2017 Jul 4.
6
SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.SELIMETRY——一项多中心碘-131剂量测定试验：临床视角
Br J Radiol. 2017 May;90(1073):20160637. doi: 10.1259/bjr.20160637. Epub 2017 Mar 14.
7
Radioiodine Therapy.放射性碘治疗
Semin Nucl Med. 2017 Mar;47(2):126-134. doi: 10.1053/j.semnuclmed.2016.10.002. Epub 2016 Nov 1.
8
Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details.经验性放射性碘治疗与剂量测定引导的放射性碘治疗的比较：细节决定成败。
J Nucl Med. 2017 May;58(5):863. doi: 10.2967/jnumed.117.190199. Epub 2017 Feb 23.
9
Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details.经验性与剂量测定引导的放射性碘治疗的比较：细节决定成败。
J Nucl Med. 2017 May;58(5):862. doi: 10.2967/jnumed.116.186643. Epub 2017 Feb 9.
10
Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.中危分化型甲状腺癌患者术后低剂量和高剂量放射性碘治疗的临床结局
Nucl Med Commun. 2017 Mar;38(3):228-233. doi: 10.1097/MNM.0000000000000636.
Zotero 插件